Mild, moderate Novel Coronavirus Infectious Disease (COVID-19) Suspended Phase 2 Trials for Fluvoxamine (DB00176)

Also known as: Mild to Moderate COVID-19 / Mild-to-moderate COVID-19

IndicationStatusPhase
DBCOND0134176 (Mild, moderate Novel Coronavirus Infectious Disease (COVID-19))Suspended2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04711863Fluvoxamine for Adults With Mild to Moderate COVID-19Treatment